Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10272087" target="_blank" >RIV/00216208:11110/14:10272087 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/14:00076233 RIV/00216208:11130/14:10272087 RIV/00216208:11140/14:10272087 RIV/61989592:15110/14:33150515 a 4 dalších
Výsledek na webu
<a href="http://www.sciencedirect.com/science/article/pii/S1078143913005097#" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1078143913005097#</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.urolonc.2013.12.007" target="_blank" >10.1016/j.urolonc.2013.12.007</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
Popis výsledku v původním jazyce
Objectives: The aim of the present study was to describe the efficacy and safety of everolimus in the treatment of metastatic renal cell carcinoma (mRCC) after administration of 1 vs. 2 prior tyrosine kinase inhibitors (TKIs). Patients and methods: A national renal information system database was used as the data source for the retrospective study. There were 483 patients who received everolimus as the second (n = 350) or the third (n = 112) targeted agent following TKIs. Results: Median progression-free survival (PFS) from the start of everolimus in the second or the third line of targeted therapy was 6.1 months for both subgroups (P = 0.863). Median total PFS from the start of the first targeted agent to progression on the third targeted agent for patients receiving 3 lines of therapy with TKI-TKI-everolimus (n = 112) and TKI-everolimus-TKI (n = 27) sequences was 28.3 months vs. 31.3 months, respectively (P = 0.16), and there was no significant difference in overall survival. PFS on
Název v anglickém jazyce
Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
Popis výsledku anglicky
Objectives: The aim of the present study was to describe the efficacy and safety of everolimus in the treatment of metastatic renal cell carcinoma (mRCC) after administration of 1 vs. 2 prior tyrosine kinase inhibitors (TKIs). Patients and methods: A national renal information system database was used as the data source for the retrospective study. There were 483 patients who received everolimus as the second (n = 350) or the third (n = 112) targeted agent following TKIs. Results: Median progression-free survival (PFS) from the start of everolimus in the second or the third line of targeted therapy was 6.1 months for both subgroups (P = 0.863). Median total PFS from the start of the first targeted agent to progression on the third targeted agent for patients receiving 3 lines of therapy with TKI-TKI-everolimus (n = 112) and TKI-everolimus-TKI (n = 27) sequences was 28.3 months vs. 31.3 months, respectively (P = 0.16), and there was no significant difference in overall survival. PFS on
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Urologic Oncology: Seminars and Original Investigations
ISSN
1078-1439
e-ISSN
—
Svazek periodika
32
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
7
Strana od-do
569-575
Kód UT WoS článku
000338090800009
EID výsledku v databázi Scopus
—